BIOMERIEUX , INC.

Biomerieux, Inc. specializes in in vitro diagnostic (IVD) devices focused on microbial identification and antimicrobial susceptibility testing. Their products include antimicrobial gradient test strips (like ETEST®), automated systems for microbial identification (such as VITEK® and VITEK® MS), fluorescent immunoassay analysers (e.g., VIDAS®), culture media (e.g., selective/differential agar and nutrient broth), and blood culture analysers (e.g., BACT/ALERT®). These devices support laboratory workflows in infectious disease diagnostics.

Biomerieux, Inc. is based in the United States, which means its devices fall under FDA regulatory jurisdiction. Since the company manufactures IVDs, its products are authorised through the FDA’s premarket authorisation processes, including 510(k) clearances or PMA approvals for Class II and Class III devices, respectively. The FDA’s UDI database lists its authorised devices, ensuring traceability and compliance tracking.

Biomerieux, Inc.’s devices are listed in the FDA’s Unique Device Identifier (UDI) database. This registry assigns a standardized identifier to each authorised device, enabling transparency in tracking and compliance. The UDI system helps healthcare providers, regulators, and distributors verify device details, including classification and authorisation status.

Biomerieux, Inc.’s devices are classified into three FDA categories: Class I (generally low-risk, with minimal regulatory controls), Class II (moderate-risk, requiring special controls to ensure safety and effectiveness), and Class III (high-risk, requiring premarket approval due to insufficient data to assure safety and performance). Classification depends on factors like the device’s intended use, potential risks, and the level of regulatory oversight required to mitigate those risks.

The primary purpose of Biomerieux, Inc.’s antimicrobial susceptibility testing devices—such as ETEST® gradient strips and VITEK® systems—is to determine the effectiveness of antibiotics against specific microorganisms. These devices help laboratories identify the minimum inhibitory concentration (MIC) of antimicrobials, enabling clinicians to prescribe targeted treatments and reduce the risk of antibiotic resistance. This supports precision medicine in infectious disease management.